A transaction-underwriting guide to specialty pharmacy M&A, including buyer demand, script volume, patient persistence, therapy and drug mix, PBM and payer access, limited-distribution drugs, accreditation, 340B relationships, DSCSA, hub services, revenue cycle, inventory, working capital, EBITDA quality, valuation, structure, integration, and seller proceeds.
A buyer-underwriting guide to specialty pharmacy acquirers, including strategic pharmacy platforms, payer- and PBM-owned buyers, pharmaceutical distributors, health-system integrators, private equity, sponsor-backed platforms, buyer fit, financing, diligence, transaction structure, integration, and seller proceeds.
By George Barsom, JD, CM&AA®, CAIA® • Last updated: July 25, 2026 Updated for compounding-pharmacy owners, 503A pharmacies, 503B outsourcing facilities, strategic acquirers, pharmaceutical-services platforms, private equity sponsors, lenders, attorneys, quality specialists, accountants, and transaction professionals evaluating sterile and nonsterile operations, product permissibility, inspections, quality systems, normalized earnings, valuation, diligence, transaction structure, and seller proceeds. Key answer:…